Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Original Article

J Liaquat Uni Med Health Sci. 2014; 13(2): 67-70

Outcome of Pregnancies Complicated by Fetal Growth Restriction

Kavita Roy, Hemlata, Najma Bano Sheikh, Pushpa Goswami.

OBJECTIVES: The purpose of this study is determine the perinatal outcome, mode of delivery
and rate of emergency caesarean section in pregnancies complicated by fetal growth restriction
STUDY DESIGN: Cross sectional study.
SETTING: Department of Obstetrics and Gynecology, Ziauddin Medical University Hospital, Karachi, from 1st December 2006 to 30th November 2007.
METHODOLOGY: During period of the study, all pregnant women with clinical suspicion of FGR
were included in this study. Diagnosis was made by history, clinical examination and by sonographic evidence. Ante partum surveillance of fetal wellbeing was done by using the kick count
chart, non-stress test and biophysical profile.
RESULTS: During period of the study 4212 deliveries were conducted, and 150 pregnancies
were complicated by fetal growth restriction (FGR). Demographic characteristics of 150 pregnancies’ complicated by FGR was recorded. The mean maternal age was 26.48 ± 4.06. The 91
(61%) women were nulliparous and 59 (39%) were multiparous. Gestational age at the time of
delivery was less than 36 weeks in 23 (15.3%) women whereas 127 (84.7%) had more than 36
weeks. 72 (48%) patients were delivered with cesarean section while 78 (52%) were delivered
vaginally. Neonatal weight was more than 1.5 kg in 147 cases while less than 1.5kg was seen in
03 cases. Total 6 / 150 (4%) perinatal mortalities were observed in FGR, Common neonatal morbidities identified were hyperbilirubinemia, respiratory distress syndrome, infections and necrotizing enterocolitis.
CONCLUSION: Our study showed that majority of fetal growth babies had weight more than 1.5
kg, with apgar score > 5.Most common neonatal morbidity seen was RDS and hyperbilirubinemia.

Key words: FGR, Gestational Age, Birth Weight, Mode of delivery

Similar Articles

Cerebral dopamine neurotrophic factor transfection in dopamine neurons using neurotensin-polyplex nanoparticles reverses 6-hydroxydopamine-induced nigrostriatal neurodegeneration.
Fernandez-Parrilla MA, Reyes-Corona D, Flores-Martinez YM, Nadella R, Bannon MJ, Escobedo L, Maldonado-Berny M, Santoyo-Salazar J, Soto-Rojas LO, Luna-Herrera C, Ayala-Davila J, Gonzalez-Barrios JA, Flores G, Gutierrez-Castillo ME, Espadas-Alvarez AJ, Martínez-Dávila IA, Nava P, Martinez-Fong D
Neural regeneration research. 2022; 17(4): 854-866

Therapeutic potential of translocator protein ligands for age-related macular degeneration.
Li X, He Z, Shu X
Neural regeneration research. 2022; 17(4): 793-794

Non-invasive gene delivery across the blood-brain barrier: present and future perspectives.
Kimura S, Harashima H
Neural regeneration research. 2022; 17(4): 785-787

GDNF to the rescue: GDNF delivery effects on motor neurons and nerves, and muscle re-innervation after peripheral nerve injuries.
Cintron-Colon AF, Almeida-Alves G, VanGyseghem JM, Spitsbergen JM
Neural regeneration research. 2022; 17(4): 748-753

Application of Nanoparticle-Mediated RNAi for Efficient Gene Silencing and Pest Control on Soybean Aphids.
Yan S, Shen J
Methods in molecular biology (Clifton, N.J.). 2022; 2360(): 307-315

Full-text options

Latest Statistics about COVID-19
• pubstat.org

Add your Article(s) to Indexes
• citeindex.org

Covid-19 Trends and Statistics
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.

ScopeMed Web Sites